Comparative Pharmacology
Head-to-head clinical analysis: HYDRAMINE versus PROMETHAZINE HYDROCHLORIDE PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRAMINE versus PROMETHAZINE HYDROCHLORIDE PLAIN.
HYDRAMINE vs PROMETHAZINE HYDROCHLORIDE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist of histamine H1 receptors, preventing histamine-mediated responses such as vasodilation, bronchoconstriction, and increased capillary permeability.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also has anticholinergic, antiemetic, and sedative properties. In the CNS, it inhibits the chemoreceptor trigger zone and vestibular apparatus, contributing to its antiemetic effect.
50-100 mg IV/IM every 4-6 hours, maximum 400 mg per day. Also available as 50 mg oral tablets.
Adults: 25 mg orally or intramuscularly every 4 to 6 hours as needed; for motion sickness, 25 mg taken 30-60 minutes before departure, then every 12 hours as needed.
None Documented
None Documented
Clinical Note
moderateDiphenhydramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
Clinical Note
moderateDiphenhydramine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
Clinical Note
moderateDiphenhydramine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diphenhydramine."
Clinical Note
moderateTerminal elimination half-life 5.7 hours, range 4.2-7.7 hours; prolonged in hepatic impairment (up to 15 hours in cirrhosis)
Terminal elimination half-life is approximately 10-19 hours in adults (mean ~16 hours). In children, half-life is shorter (~7-14 hours). Clinical context: Once-daily dosing may be insufficient for continuous sedation; requires every 6-8 hour dosing for sustained effect.
Primarily renal (95%) as metabolites; <5% unchanged; 5% fecal
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~70% of elimination, with 20-30% as unchanged drug in urine. Fecal excretion is minimal (~5%).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic
Diphenhydramine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diphenhydramine."